J.R. DeVita
Vice President, Corporate Development and Investor Relations
Replay available
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call
Nuvation Bio Inc. (NYSE: NUVB) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. David Hung
Founder, President, and Chief Executive Officer
Colleen Sjogren
Chief Commercial Officer
Philippe Sauvage
Chief Financial Officer
Farzan Haque
Analyst, Jefferies
Gregory Renza
Analyst, Truist Securities
Mayank Mamdani
Analyst, B. Riley Securities
Michael Yee
Analyst, UBS
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Nuvation Bio Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.215 Hello and welcome to Novation Bio's second quarter 2026 financial results 00:00:05.215 -- 00:00:10.339 and business update call. Today's call is being recorded and a replay will 00:00:10.339 -- 00:00:15.383 be available on the company's website. All participants are currently in a listen-only 00:00:15.383 -- 00:00:20.607 mode. A brief question and answer session will follow the prepared remarks. 00:00:20.607 -- 00:00:23.029 Now, I'd like to turn the call over to J.R. 00:00:23.029 -- 00:00:29.012 DeVita, Vice President of Corporate Development and Investor Relations at Novation Bio. 00:00:29.012 -- 00:00:31.833 Please go ahead. 00:00:33.975 -- 00:00:39.099 Thank you and good morning, everyone. Earlier today, we issued a press release summarizing 00:00:39.099 -- 00:00:44.322 our financial results for the quarter ending June 30th, 2026 and provided 00:00:44.322 -- 00:00:49.906 a business update. The press release is available on the investor section of our website 00:00:49.906 -- 00:00:52.006 at newvationbio.com. 00:00:53.430 -- 00:00:58.235 Today's call includes forward-looking statements, including statements about the therapeutic 00:00:58.235 -- 00:01:01.879 and commercial potential of Ibtrozi and Safucitinib, 00:01:01.879 -- 00:01:07.044 our development plans for Safucitinib and our drug-drug conjugate platform, along 00:01:07.044 -- 00:01:10.628 with our plans for future updates from these programs, 00:01:10.628 -- 00:01:15.773 the components of our anticipated product revenue, expected milestone payments, and our 00:01:15.773 -- 00:01:17.645 cash runway. 00:01:17.645 -- 00:01:23.691 because such statements deal with future events and are subject to many risks and uncertainties, 00:01:23.691 -- 00:01:28.795 actual results may dif...